Description
Administration
– May be taken with or without food
Storage
– Store between 20°C and 25°C (68°F to 77°F)
Monitoring
– Lymphocyte count (baseline and every 3 months thereafter)
– Neutrophil/platelet counts (baseline, after 4 to 8 weeks, and every 3 months thereafter)
– Hemoglobin (baseline, after 4 to 8 weeks, and every 3 months thereafter)
– Lipids (4 to 8 weeks after therapy initiation and periodically)
– LFTs
– Viral hepatitis (prior to initiating therapy in accordance with clinical guidelines);
– Signs/symptoms of infections (including tuberculosis) during and after therapy
– Abdominal symptoms
– Skin examinations (periodically, in patients at increased risk for skin cancer)
– Heart rate and blood pressure at baseline and periodically thereafter
